Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.704920
Title: Discovery of Bcl-3 inhibitors for the potential treatment of metastatic breast cancer
Author: Bordoni, Cinzia
ISNI:       0000 0004 6057 8189
Awarding Body: Cardiff University
Current Institution: Cardiff University
Date of Award: 2016
Availability of Full Text:
Access through EThOS:
Full text unavailable from EThOS. Restricted access.
Access through Institution:
Abstract:
In HER-2 positive metastatic breast cancer, the proto-oncogene Bcl-3 was found to be overexpressed. Bcl-3 acts as a transcriptional co-activator: it forms a ternary complex with DNA and homodimer (p50)2 and stimulates the transcription of a different panel of genes in the metastatic progression of the breast cancer. Its exact role in endogenous tumours is still unknown. In vivo knockdown studies shown, that Bcl-3 deficiency did not affect the primary tumour, but it reduced the occurrence of metastases by 80% without any effects on the normal mammary gland function. Patients with this type of tumour have a poor prognosis, do not respond to the typical treatment or show resistance and side effects to the usual therapeutic options. Hence, there is an urgent need to find new candidate drugs. A virtual screening targeted against a newly identified Bcl-3 binding pocket allowed the identification of 10 molecules, tested in vitro cell based assays. Four molecules were active. In this thesis, different analogues of these four hit compounds were synthesised. Based on docking studies, another two scaffolds were designed. The non-cytotoxic profile of the new analogues was assessed using the cell titer blue assay. The activity of the compounds was established using the colony forming assay (CFA). To prove the Bcl-3/p50 interaction, immunoprecipitation and co-immunoprecipitation were performed. None of the compounds was cytotoxic. Some of them exhibited a promising activity in the CFA. One molecule exhibited an interesting activity profile both in vitro and in vivo and in pharmacokinetic studies and it has been forwarded into full pre-clinical development.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.704920  DOI: Not available
Keywords: RC0254 Neoplasms. Tumors. Oncology (including Cancer) ; RM Therapeutics. Pharmacology
Share: